Therapeutic options for metastatic pancreatic ductal adenocarcinoma (PDAC) remain limited, with second-line treatments typically yielding modest benefit. Activation of the RAS pathway, most commonly driven by KRAS mutations, occurs in the vast majority of PDAC cases and represents a critical oncogenic dependency.